Nebraska Medicaid and semaglutide
Wegovy for weight loss: no. Covered for heart event risk reduction in adults 45 to 74, or a liver condition (MASH) in adults 18 and older. Prior authorization required. Ozempic for weight loss: no. Preferred drug in the diabetes class. Requires a type 2 diabetes diagnosis, with a metformin trial or heart disease tied to diabetes.; for type 2 diabetes Nebraska Medicaid must cover it. Read from Nebraska Department of Health and Human Services, Medicaid pharmacy program (Prime Therapeutics) documents Nov 6, 2026.
Wegovy · Nebraska DHHS Medicaid, via Prime Therapeutics State Government Solutions
“Semaglutide (Wegovy) is covered for the reduction of the risk of major adverse cardiovascular events (MACE)”
read Nov 6, 2026
Ozempic · Nebraska DHHS Medicaid, via Prime Therapeutics State Government Solutions
“Preferred agents require a diagnosis of Type II diabetes AND a trial and failure or intolerance to metformin”
read Nov 6, 2026
In 2025 Nebraska Medicaid paid for 24,156 semaglutide prescriptions (Ozempic, Rybelsus, Wegovy), 65% of its GLP-1 prescriptions and 36th of the 50 states and DC. It reimbursed $23.1 million before rebates, $954 a prescription against $1,104 nationally.
| Brand | Prescriptions | Medicaid paid | Per Rx |
|---|---|---|---|
| Ozempic | 23,578 | $22.5 million | $954 |
| Rybelsus | 462 | $407,277 | $882 |
| Wegovy | 116 | $149,230 | $1,286 |
Semaglutide in the states around Nebraska
| State | Sell semaglutide, ship there | Cheapest | Medicaid Rx, 2025 | Medicaid, Wegovy for weight loss |
|---|---|---|---|---|
| Nebraska | 19 | $39/moWellmedr | 24,156 | Medicaid Wegovy: No |
| Colorado | 19 | $39/moWellmedr | 26,771 | Medicaid Wegovy: No |
| Iowa | 19 | $39/moWellmedr | 53,645 | Medicaid Wegovy: No |
| Kansas | 19 | $39/moWellmedr | 13,271 | Medicaid Wegovy: Yes |
| Missouri | 18 | $39/moWellmedr | 75,811 | Medicaid Wegovy: No |
| South Dakota | 19 | $39/moWellmedr | 7,210 | Medicaid Wegovy: No |
| Wyoming | 19 | $39/moWellmedr | 593 | Medicaid Wegovy: No |



